Dobson A J, Jamrozik K D, Hobbs M, Heller R F, Steele P L, Parsons R, Thompson P
Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, NSW.
Aust N Z J Med. 1993 Feb;23(1):12-8. doi: 10.1111/j.1445-5994.1993.tb00531.x.
Coronary mortality rates are significantly higher in Newcastle than Perth. In this paper we examine the extent to which this might be due to differences in medical treatment and case fatality. Population-based disease registers were used to identify all cases of non-fatal definite myocardial infarction (MI) and coronary death in people aged 25-64 years in the study populations between July 1988 and June 1990. Case fatality (at 28 days from onset of symptoms) was not significantly different between the centres. Thrombolytic therapy was used for one third of all hospitalised events in both centres. Other drugs of proven benefit were, however, used more often in Perth than in Newcastle. For example, during hospitalisation 74% of patients in Perth received beta-blockers compared with 41% in Newcastle (difference = 33%, 95% confidence interval (CI): 28%, 37%) and 85% of patients in Perth compared with 72% in Newcastle received aspirin (difference = 13%, 95% CI: 9%, 17%). Median lengths of stay in a coronary care unit (CCU) and total hospital stay were one day shorter in Perth. As case fatality was similar, the differences in mortality rates can be attributed mainly to differences in attack rates. Greater use of cardio-active drugs in Perth apparently did not result in improved short-term outcome although potential long-term benefits cannot be judged yet.
纽卡斯尔的冠心病死亡率显著高于珀斯。在本文中,我们研究了这一情况在多大程度上可能是由于医疗治疗和病死率的差异所致。基于人群的疾病登记册用于识别1988年7月至1990年6月期间研究人群中25 - 64岁的所有非致命性确诊心肌梗死(MI)病例和冠心病死亡病例。两个中心之间的病死率(症状出现后28天)没有显著差异。两个中心三分之一的住院病例都使用了溶栓治疗。然而,在珀斯,其他已证实有益的药物使用频率高于纽卡斯尔。例如,住院期间,珀斯74%的患者接受了β受体阻滞剂治疗,而纽卡斯尔为41%(差异 = 33%,95%置信区间(CI):28%,37%);珀斯85%的患者接受了阿司匹林治疗,而纽卡斯尔为72%(差异 = 13%,95% CI:9%,17%)。珀斯冠心病监护病房(CCU)的中位住院时间和总住院时间均短一天。由于病死率相似,死亡率的差异主要可归因于发病率的差异。尽管尚未能判断潜在的长期益处,但珀斯更多地使用心脏活性药物显然并未带来短期预后的改善。